Topical bromfenac transiently delays axotomy-induced retinal ganglion cell loss. 2019

Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
Departamento de Oftalmología, Facultad de Medicina, Universidad de Murcia, and Grupo de Oftalmología Experimental, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Virgen de la Arrixaca), Murcia, Spain.

Optic nerve axotomy in rodents allows detailed studies of the effect of different treatments on the survival of central nervous system neurons, the retinal ganglion cells (RGCs). Here we have analyzed the neuroprotective effect of topical bromfenac treatment, a nonsteroidal anti-inflammatory drug (NSAID) used in clinic to ameliorate post-operative inflammation, on axotomized rat RGCs. The left optic nerve of adult rats was subjected to optic nerve crush (ONC). Half of the rats were treated with a topical instillation of saline. On the other half, immediately after the surgery, 2 drops of bromfenac (0.09% Yellox; Bausch & Lomb) were instilled, and then every 12 h until analysis. Retinas in both groups were dissected 3, 5, 7, 9 and 14 days after ONC (n = 4-8/time point/group). Toxicity of bromfenac was assessed in intact retinas treated during 14 days (n = 6). Intact untreated retinas were used as control of the RGC population. RGCs were identified by Brn3a immunodetection and automatically quantified. Our results show that bromfenac does not cause RGC loss in intact retinas. In the injured groups, the number of RGCs at 7, 9 and 14 days after the lesion was significantly higher in treated vs. untreated retinas. To our knowledge this is the first report showing that a topical treatment with a NSAIDs delays axotomy-induced RGC loss and indicates that treatment with NSAIDs could be used as conjunctive therapy in diseases that proceed with optic nerve damage.

UI MeSH Term Description Entries
D009900 Optic Nerve The 2nd cranial nerve which conveys visual information from the RETINA to the brain. The nerve carries the axons of the RETINAL GANGLION CELLS which sort at the OPTIC CHIASM and continue via the OPTIC TRACTS to the brain. The largest projection is to the lateral geniculate nuclei; other targets include the SUPERIOR COLLICULI and the SUPRACHIASMATIC NUCLEI. Though known as the second cranial nerve, it is considered part of the CENTRAL NERVOUS SYSTEM. Cranial Nerve II,Second Cranial Nerve,Nervus Opticus,Cranial Nerve, Second,Cranial Nerves, Second,Nerve, Optic,Nerve, Second Cranial,Nerves, Optic,Nerves, Second Cranial,Optic Nerves,Second Cranial Nerves
D001969 Bromobenzenes Derivatives of benzene in which one or more hydrogen atoms on the benzene ring are replaced by bromine atoms.
D002452 Cell Count The number of CELLS of a specific kind, usually measured per unit volume or area of sample. Cell Density,Cell Number,Cell Counts,Cell Densities,Cell Numbers,Count, Cell,Counts, Cell,Densities, Cell,Density, Cell,Number, Cell,Numbers, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D001577 Benzophenones Derivatives of benzophenone (with the structural formula phenyl-(C

Related Publications

Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
January 2019, Frontiers in neuroscience,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
November 2017, Journal of neuroinflammation,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
May 2002, The Journal of comparative neurology,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
December 2008, Prostaglandins, leukotrienes, and essential fatty acids,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
May 1993, Journal of the neurological sciences,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
March 1989, The Journal of comparative neurology,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
August 2002, Experimental eye research,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
May 1998, Vision research,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
May 2004, Investigative ophthalmology & visual science,
Giuseppe Rovere, and Francisco M Nadal-Nicolás, and Paloma Sobrado-Calvo, and María P Villegas-Pérez, and Manuel Vidal-Sanz, and Marta Agudo-Barriuso
May 2011, Experimental eye research,
Copied contents to your clipboard!